Recent advances in managing non-small-cell lung cancer: 4. Chemotherapy of metastatic cancer

Medical Journal of Australia

Volumn 166, Issue SUPPL., 1997, Pages

  Clarke, Stephen J ^a,b   Boyer, Michael J ^a  

^a SYDNEY CANCER CENTRE   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN C; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE; TOPOTECAN; VINBLASTINE; VINDESINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; HUMAN; LUNG NON SMALL CELL CANCER;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DNA TOPOISOMERASES, TYPE I; HUMANS; LUNG NEOPLASMS; PACLITAXEL; PALLIATIVE CARE; TAXOIDS;

EID: 0030916618     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ginsberg RJ, Kris MG, Armstrong JG. Cancer of the lung: non-small cell lung cancer. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia: JB Lippincott, 1993; 673-723.
2. Arriagada R, Le Chevalier T, Quoix E, et al. Effect of chemotherapy on locally advanced non-small cell lung carcinoma: a randomized study of 353 patients. GETCB (Groupe d'Étude et Traitement des Cancers Bronchiques), FNCLCC (Federation Nationale des Centres de Lutte contre le Cancer) and the CEBI trialists. Int J Radiat Oncol Biol Phys 1991; 20: 1183-1190.
3. Ellis PA, Smith IE, Hardy JR, et al. Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer 1995; 71: 366-370.
4. Cullen MH. Trials with mitomycin, ifosfamide and cisplatin In non-small cell lung cancer. Lung Cancer 1995; 12 Suppl 1: S95-S106.
5. Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899-909.
6. Shepherd FA. Future directions in the treatment of non-small cell lung cancer. Semin Oncol 1994; 21 Suppl 4: S48-S62.
7. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
8. Francis PA, Kris MG, Rigas JR, Grant SC, Miller VA. Paclitaxel (taxol) and docetaxel (taxotere): active chemotherapeutic agents in lung cancer. Lung Cancer 1995; 12 Suppl 1: S163-S172.
9. Ettinger DS. Overview of paclitaxel (taxol) In advanced lung cancer. Semin Oncol 1993; 20: 46-49.
10. Rigas JR. Docetaxel in stage III and IV non-small cell lung cancer. Eur J Cancer 1995; 31A Suppl 4: S18-S20.
11. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995; 13: 645-651.
12. Sorensen JB. Gemcitabine in non-small cell lung cancer. Lung Cancer 1995; 12 Suppl 1: S173-S175.
13. Ardizzoni A. Camptothecin analogues in the treatment of non-small cell lung cancer. Lung Cancer 1995; 12 Suppl 1: S177-S185.
14. Crawford J. Vinorelbine (navelbine) in non-small cell lung cancer: future directions. Semin Oncol 1994; 21: 85-88.
15. Brundage MD, Davidson JR, Mackillop WJ. Trading treatment toxicity for survival in advanced non-small cell lung cancer. J Clin Oncol 1997; 15: 330-340.
16. Klatersky J, Sculier JR LaCroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer. European Organization for Research and Treatment of Cancer protocol 07861. J Clin Oncol 1990; 8: 1556-1562.
17. Jaakkimainen L, Goodwin PJ, Pater J, et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 1990; 8: 1301-1309.
18. Edelman MJ, Gandara DR. Promising new agents in the treatment of non-small cell lung cancer. Cancer Chemother Pharmacol 1996; 37: 385-393.
19. Bonomi P, Kim K, Chang A, Johnson D, Phase III trial comparing etoposide-cisplatin versus taxol with cisplatin-G-CSF versus taxol-ci splatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group Trial [abstract]. Proc Am Soc Clin Oncol 1996; 15: 382.
20. Giaccone G, Splinter T, Postmus P, et al. Paclitaxel-cisplatin versus teniposide-cisplatln In advanced non-small cell lung cancer (NSCLC) [abstract]. Proc Am Soc Clin Oncol 1996; 15: 373.